Suplatast tosilate

A Th2 cytokine inhibitor that attenuates IL-2, IL-5 and IL-13 production and has no effect on IFN-γ production; suppresses IgE production, eosinophil infiltration and histamine release; exhibits antiasthmatic, anti-inflammatory and antifibrotic activity in vivo and is orally active.Allergy Approved (In Vitro) :IPD-1151T (1-10 μM; 10 d) induces a concentration-dependent suppression of purified allergen (Cry j 1) -dependent IgE synthesis in autologous B cell cultures mediated by SN-4, without significantly affecting the IgG synthesis.IPD-1151T (1-10 μM; 24 h) clearly depresses phytohemagglutinin (PHA) -induced expression of IL-4 mRNA in normal peripheral blood mononuclear cells (PBMC) . (In Vivo) :Suplatast Tosilate (100 mg/kg; once daily for 21 d) inhibits the production of Th2 cytokines, which inhibits eosinophil infiltration into the murine airway, IgE synthesis, and development of BHR, in a murine model of asthma.Suplatast Tosilate (100 μg/kg; once daily for 14 d) strongly suppresses immunoglobulin E contents in serum.